Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.
"Cancer is a complex disease which requires innovative therapeutic approaches. Amgen is exploring numerous biologic pathways to develop novel therapies to treat cancer and lessen the side effects of cancer and its treatment," said Willard Dere, M.D., senior vice president and international chief medical officer at Amgen. "The data being presented at this year's ESMO Congress, including new denosumab and AMG 386 analyses, reflect the breadth and diversity of Amgen's oncology portfolio."
Abstracts will be available on the ESMO website at http://www.esmo.org following the meeting.
Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds